Progen Industries Limited New Placement Terms Announced

Progen Industries Limited New Placement Terms Announced 


BRISBANE, Australia, Oct. 31  /PRNewswire-FirstCall/ -- Progen Industries
Limited  today announced that the terms of the placement agreement announced on
September 18 have been renegotiated.

As a consequence of the Nasdaq Biotechnology Index falling greater than 10%
since the date of signing of the agreement and today, the terms of the placement
agreement signed with Taylor Collison Limited (Taylor Collison) on September 18
are no longer valid.  Progen and Taylor Collison entered into a new
unconditional agreement where 3.8 million shares were placed at $1.40 per share
raising a total $5.3 million. This placement is in accordance with ASX Listing
Rule 7.1 subject to shareholders ratification at today's Annual General Meeting
of the Share Purchase Placement in June. The new funds will be applied to pursue
a strategic growth strategy for the company that intends to build a robust
pipeline of drug candidates that will support the long-term objectives of the
company.

Stephen Chang, Progen's Chairman commented "This capital injection will bring
our cash reserves to $15 million and with our current burn rate this will give
us over 24 months of cash reserves. As we look to the future, we are determined
to focus our resources on what we do best, and what holds the greatest value
proposition, and that is the drug development.  The success we have had so far
in human clinical trials, with our lead drug candidate, PI-88, attests to our
ability in the area of oncology drug development, and now it is time for us to
develop a larger portfolio of future drugs to follow on after PI-88."

Progen's clinical trial program is showing great promise. The first PI-88 Phase
II trial, which was in Multiple Myeloma, has been concluded with PI-88 meeting
the trial efficacy endpoints. PI-88 is also yielding encouraging data as a
single-agent in a Phase I solid tumor trial, where one third of cancer patients
treated to date have experienced stable disease over periods up to 27 months. 
These data are forming an important part of the licensing package of PI-88.  The
out-licensing push for PI-88 is now gaining momentum and ongoing discovery and
in-licensing activities will be supported by capital from the current raising.

   Contact:
   Sarah Meibusch
   Progen Industries Limited
   T: [phone]
   E: 

DATASOURCE: Progen Industries Limited



CONTACT: Sarah Meibusch of Progen Industries Limited, [phone],

Copyright